文献速递真菌感染

难治性侵袭性曲霉病与耐药性侵袭性曲霉病

Refractory versus resistant invasive aspergillosis.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本文讨论确诊和临床诊断侵袭性曲霉病治疗失败与难治性的定义、评估和管理方法,分析难治性可源于基础疾病严重程度、抗真菌药物暴露不足、影像学假性进展或曲霉属内在/获得性耐药,尤其烟曲霉唑类耐药在增加且可见于未用过唑类的患者,强调即使药敏结果未回报也需密切评估并可能调整治疗。

要点

  • 治疗失败评估需综合考虑宿主基础疾病严重程度、真菌毒力与药敏、以及治疗时机、剂量、疗效、杀菌/抑菌、毒性和相互作用。
  • 无耐药证据的难治性可能反映基础疾病/感染严重导致起效延迟、药物暴露不足或中性粒细胞恢复所致影像学假性恶化。
  • 烟曲霉唑类耐药在增加,包括未用过唑类的患者,与农业和园艺唑类杀菌剂使用相关。

核心结论

  • 尽管有显著进展,侵袭性曲霉病的管理仍具挑战性且治疗失败常见,最终结局受宿主、真菌和治疗等多因素影响。
  • 难治性可源于无耐药时的基础疾病严重程度、抗真菌药物暴露不足或假性失败,也可源于曲霉属内在耐药或通常敏感菌种的获得性耐药。
  • 尽管诊断和耐药检测已大幅改进,耐药报告时间往往仍不理想,需要在药敏已知前密切评估并可能调整管理。

研究设计与样本

  • 本文为综述,讨论确诊和临床诊断侵袭性曲霉病背景下临床难治性/治疗失败的各种定义、评估和管理方法。

主要发现

  • 难治性在无药物耐药时可能反映治疗开始时基础疾病/感染的严重程度延长了起效时间。
  • 难治性也可能反映因依从性差、剂量不当或药物代谢增加所致的抗真菌药物暴露不足。
  • 难治性也可能反映因中性粒细胞恢复导致影像学恶化所致的「假性」失败。
  • 获得性耐药最常见于烟曲霉,其唑类耐药在增加,且包括未用过唑类的患者,与农业和园艺中唑类杀菌剂使用相关的耐药有关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite notable progress, the management of invasive aspergillosis (IA) remains challenging and treatment failures are common. The final patient outcome is subject to multiple factors including the host (the severity of the underlying conditions), the fungus (the virulence and susceptibility pattern of the Aspergillus species involved), and the therapy (the timing related to severity of infection and choice of therapy-dose, efficacy, cidal versus static, toxicity and interaction). Consequently, assessment of failure is complex yet crucial in order to ensure appropriate management. Refractoriness in absence of drug resistance may reflect severity of the underlying disease/infection at the time of initiation of therapy prolonging time to response. It may also reflect a suboptimal antifungal drug exposure due to poor compliance, inappropriate dosing or increased drug metabolism, or it may reflect 'pseudo' failure due to worsening of imaging due to recovery of neutrophils. Refractoriness may also be related to inherent drug resistance in various Aspergillus species or acquired resistance in a normally susceptible species. The latter scenario is mostly encountered in A. fumigatus, where azole resistance is increasing and includes azole-naive patients due to resistance related to azole fungicide use in agriculture and horticulture. Although diagnostics and resistance detection have been greatly improved, the time to resistance reporting is often still suboptimal, which calls for close assessment and potentially management changes even before the susceptibility is known. In this article we address the various definitions and approaches to assessment and management of clinical refractoriness/failure in the setting of proven and probable IA.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Arendrup MC, Cordonnier C. Refractory versus resistant invasive aspergillosis. J Antimicrob Chemother. 2025. PMID: 40085537. doi:10.1093/jac/dkaf003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。